간행물

대한간학회> Clinical and Molecular Hepatology(대한간학회지)

Clinical and Molecular Hepatology(대한간학회지) update

Clinical and Molecular Hepatology (CMH)

  • : 대한간학회
  • : 의약학분야  >  내과학
  • : KCI등재
  • : SCOPUS
  • : 연속간행물
  • : 계간
  • : 2287-2728
  • :
  • : 대한간학회지()→Korean Journal of Hepatology(2004~)→대한간학회지(2012~)

수록정보
수록범위 : 1권1호(1995)~25권1호(2019) |수록논문 수 : 4,552
Clinical and Molecular Hepatology(대한간학회지)
25권1호(2019년 03월) 수록논문
최근 권호 논문
| | | |

KCI등재 SCOPUS

1Recent research trends and updates on nonalcoholic fatty liver disease

저자 : Jeong-ju Yoo , Won Kim , Moon Young Kim , Dae Won Jun , Sang Gyune Kim , Jong-eun Yeon , Jin Woo Lee , Yong Kyun Cho , Sang Hoon Park , Joo Hyun Sohn

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 25권 1호 발행 연도 : 2019 페이지 : pp. 1-11 (11 pages)

다운로드

(기관인증 필요)

초록보기

Nonalcoholic fatty liver disease (NAFLD), together with metabolic syndrome and obesity, has shown a rapid increase in prevalence worldwide and is emerging as a major cause of chronic liver disease and liver transplantation. Among the various phenotypes of NAFLD, nonalcoholic steatohepatitis (NASH) is highly likely to progress to development of endstage liver disease and cardiometabolic disease, resulting in liver-related and non-liver-related mortality. Nonetheless, there is no standardized pharmacotherapy against NASH and many drugs are under development in ongoing clinical trials. To develop a successful anti-NASH drug, it is necessary to select an appropriate target population and treatment outcomes depending on whether the mode of action is anti-metabolic, anti-inflammatory or anti-fibrotic. Recently, innovative surrogate markers have been investigated to replace hard outcomes such as liver histology and mortality and reduce the clinical trial duration. Currently, several drugs with fast track designation are being tested in phase III clinical trials, and many other drugs have moved into phase II clinical trials. Both lean NAFLD and typical obese NAFLD have been extensively studied and genetic variants such as PNPLA3 and TM6SF2 have been identified as significant risk factors for lean NAFLD. In the near future, noninvasive biomarkers and effective targeted therapies for NASH and associated fibrosis are required to develop precision medicine and tailored therapy according to various phenotypes of NAFLD.

KCI등재 SCOPUS

2Pathologic differential diagnosis of metastatic carcinoma in the liver

저자 : Jeong Hwan Park , Jung Ho Kim

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 25권 1호 발행 연도 : 2019 페이지 : pp. 12-20 (9 pages)

다운로드

(기관인증 필요)

초록보기

The liver is one of the most common sites to which malignancies preferentially metastasize. Although a substantial number of liver malignancies are primary tumors, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, the metastasis of carcinomas to the liver is relatively common and frequently encountered in clinical settings. Representative carcinomas that frequently metastasize to the liver include colorectal carcinoma, breast carcinoma, neuroendocrine tumors, lung carcinoma, and gastric carcinoma. The diagnostic confirmation of suspected metastatic lesions in the liver is generally achieved through a histopathologic examination of biopsy tissues. Although morphology is the most important feature for a pathologic differential diagnosis of metastatic carcinomas, immunohistochemical studies facilitate the differentiation of metastatic carcinoma origins and subtypes. Useful immunohistochemical markers for the differential diagnosis of metastatic carcinomas in the liver include cytokeratins (CK7, CK19, and CK20), neuroendocrine markers (CD56, synaptophysin, and chromogranin A), and tissue-specific markers (CDX2, SATB2, TTF-1, GCDFP-15, mammaglobin, etc.). Here, we provide a brief review about the pathologic differential diagnosis of major metastatic carcinomas in the liver.

KCI등재 SCOPUS

3Radiomics and radiogenomics of primary liver cancers

저자 : Woo Kyoung Jeong , Neema Jamshidi , Ely Richard Felker , Steven Satish Raman , David Shinkuo Lu

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 25권 1호 발행 연도 : 2019 페이지 : pp. 21-29 (9 pages)

다운로드

(기관인증 필요)

초록보기

Concurrent advancements in imaging and genomic biomarkers have created opportunities to identify noninvasive imaging surrogates of molecular phenotypes. In order to develop such imaging surrogates radiomics and radiogenomics/imaging genomics will be necessary; there has been consistent progress in these fields for primary liver cancers. In this article we evaluate the current status of the field specifically with regards to hepatocellular carcinoma and intrahepatic cholangiocarcinoma, highlighting some of the up and coming results that were presented at the annual Radiological Society of North America Conference in 2017. There are an increasing number of studies in this area with a bias towards quantitative feature measurement, which is expected to benefit reproducibility of the findings and portends well for the future development of biomarkers for diagnosis, prognosis, and treatment response assessment. We review some of the advancements and look forward to some of the exciting future applications that are anticipated as the field develops.

KCI등재 SCOPUS

4Discussion on critical points for a tailored therapy to cure hepatitis C virus infection

저자 : Nadia Marascio , Angela Quirino , Giorgio Settimo Barreca , Luisa Galati , Chiara Costa , Vincenzo Pisani , Maria Mazzitelli , Giovanni Matera , Maria Carla Liberto , Alfredo Foc , Carlo Torti

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 25권 1호 발행 연도 : 2019 페이지 : pp. 30-36 (7 pages)

다운로드

(기관인증 필요)

초록보기

Hepatitis C virus (HCV) infects around 71 million people worldwide and in 2018 it is still a major health problem. Since 2011, anti-HCV therapy with availability of direct-acting antiviral drugs has revolutionized the clinical response and paved the way to eradication strategies. However, despite the high rate of sustained virological response, treatment failure may occur in a limited percentage of patients, possibly due to resistance-associated substitutions (RASs), either emergent or pre-existent even in minority viral populations. Clearly this problem may impair success of eradication strategies. With this background, several questions marks still exist around HCV treatment, including whether pan-genotypic treatments with complete effectiveness in any clinical conditions really exist outside clinical trials, the actual cost-effectiveness of genotyping testing, and utility of RAS detection in viral quasispecies by next generation sequencing approach. In this review, we describe these critical points by discussing recent literature data and our research experience.

다운로드

(기관인증 필요)

초록보기

KCI등재 SCOPUS

6Can hepatic steatosis really promote hepatitis B viral hepatocarcinogenesis? The jury is out on.

저자 : Won Kim

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 25권 1호 발행 연도 : 2019 페이지 : pp. 40-41 (2 pages)

다운로드

(기관인증 필요)

초록보기

KCI등재 SCOPUS

7Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillarassociated protein 4 in hepatitis C patients

저자 : Christian Mlleken , Maike Ahrens , Anders Schlosser , Julia Dietz , Martin Eisenacher , Helmut E , Meyer , Wolff Schmiegel , Uffe Holmskov , Christoph Sarrazin , Grith Lykke Sorensen , Barbara Sitek , Thilo

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 25권 1호 발행 연도 : 2019 페이지 : pp. 42-51 (10 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: An estimated 80 million people worldwide are infected with viremic hepatitis C virus (HCV). Even after eradication of HCV with direct acting antivirals (DAAs), hepatic fibrosis remains a risk factor for hepatocarcinogenesis. Recently, we confirmed the applicability of microfibrillar-associated protein 4 (MFAP4) as a serum biomarker for the assessment of hepatic fibrosis. The aim of the present study was to assess the usefulness of MFAP4 as a biomarker of liver fibrosis after HCV eliminating therapy with DAAs.
Methods: MFAP4 was measured using an immunoassay in 50 hepatitis C patients at baseline (BL), the end-of-therapy (EoT), and the 12-week follow-up (FU) visit. Changes in MFAP4 from BL to FU and their association with laboratory parameters including alanine aminotransferase (ALT), aspartate aminotransferase (AST), platelets, the AST to platelet ratio index (APRI), fibrosis-4 score (FIB-4), and albumin were analyzed.
Results: MFAP4 serum levels were representative of the severity of hepatic fibrosis at BL and correlated well with laboratory parameters, especially APRI (Spearman correlation, R²=0.80). Laboratory parameters decreased significantly from BL to EoT. MFAP4 serum levels were found to decrease from BL and EoT to FU with high statistical significance (Wilcoxon P<0.001 for both).
Conclusions: Our findings indicate that viral eradication resulted in reduced MFAP4 serum levels, presumably representing a decrease in hepatic fibrogenesis or fibrosis. Hence, MFAP4 may be a useful tool for risk assessment in hepatitis C patients with advanced fibrosis after eradication of the virus.

KCI등재 SCOPUS

8Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B

저자 : Yun Bin Lee , Yeonjung Ha , Young Eun Chon , Mi Na Kim , Joo Ho Lee , Hana Park , Kwang-il Kim , Soo-hwan Kim , Kyu Sung Rim , Seong Gyu Hwang

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 25권 1호 발행 연도 : 2019 페이지 : pp. 52-64 (13 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: Nonalcoholic fatty liver disease (NAFLD) is becoming a worldwide epidemic, and is frequently found in patients with chronic hepatitis B (CHB). We investigated the impact of histologically proven hepatic steatosis on the risk for hepatocellular carcinoma (HCC) in CHB patients without excessive alcohol intake.
Methods: Consecutive CHB patients who underwent liver biopsy from January 2007 to December 2015 were included. The association between hepatic steatosis (≥ 5%) and subsequent HCC risk was analyzed. Inverse probability weighting (IPW) using the propensity score was applied to adjust for differences in patient characteristics, including metabolic factors.
Results: Fatty liver was histologically proven in 70 patients (21.8%) among a total of 321 patients. During the median (interquartile range) follow-up of 5.3 (2.9-8.3) years, 17 of 321 patients (5.3%) developed HCC: 8 of 70 patients (11.4%) with fatty liver and 9 of 251 patients (3.6%) without fatty liver. The five-year cumulative incidences of HCC among patients without and with fatty liver were 1.9% and 8.2%, respectively (P=0.004). Coexisting fatty liver was associated with a higher risk for HCC (adjusted hazards ratio [HR], 3.005; 95% confidence interval [CI], 1.122-8.051; P =0.03). After balancing with IPW, HCC incidences were not significantly different between the groups (P =0.19), and the association between fatty liver and HCC was not significant (adjusted HR, 1.709; 95% CI, 0.404-7.228; P =0.47).
Conclusions: Superimposed NAFLD was associated with a higher HCC risk in CHB patients. However, the association between steatosis per se and HCC risk was not evident after adjustment for metabolic factors.

KCI등재 SCOPUS

9Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection

저자 : Shinya Sato , Kei Moriya , Masanori Furukawa , Soichiro Saikawa , Tadashi Namisaki , Mitsuteru Kitade , Hideto Kawaratani , Kosuke Kaji , Hiroaki Takaya , Naotaka Shimozato , Yasuhiko Sawada , Kenichiro Seki

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 25권 1호 발행 연도 : 2019 페이지 : pp. 65-73 (9 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: L-carnitine not only alleviates hyperammonemia and reduces muscle cramps in patients with liver cirrhosis, but also improves anemia in patients with chronic hepatitis and renal dysfunction. This study prospectively evaluated the preventative efficacy of L-carnitine supplementation against hemolytic anemia during antiviral treatment using ribavirin in patients with hepatitis C virus (HCV)-related chronic liver disease.
Methods: A total of 41 patients with chronic hepatitis were consecutively enrolled in this study. Group A (n=22) received sofosbuvir plus ribavirin for 3 months, whereas group B (n=19) was treated with sofosbuvir, ribavirin, and L-carnitine. Hemoglobin concentration changes, the effects of antiviral treatment, and the health status of patients were analyzed using short form-8 questionnaires.
Results: A significantly smaller decrease in hemoglobin concentration was observed in group B compared to group A at every time point. Moreover, the prescribed dose intensity of ribavirin in group B was higher than that of group A, resulting in a higher ratio of sustained virological response (SVR) 24 in group B compared with group A. The physical function of patients in group B was also significantly improved compared to group A at the end of antiviral treatment.
Conclusions: L-carnitine supplementation alleviates ribavirin-induced hemolytic anemia in patients with HCV and helps relieve the physical burden of treatment with ribavirin-containing regimens. These advantages significantly increase the likelihood of achieving SVR.

KCI등재 SCOPUS

10Safety margin of embolized area can reduce local recurrence of hepatocellular carcinoma after superselective transarterial chemoembolization

저자 : Kittipitch Bannangkoon , Keerati Hongsakul , Teeravut Tubtawee , Teerha Piratvisuth

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 25권 1호 발행 연도 : 2019 페이지 : pp. 74-85 (12 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: We aimed to determine the relationship between the safety margin of an embolized area and local tumor recurrence (LTR) of patients with hepatocellular carcinoma (HCC) who underwent superselective transarterial chemoembolization (TACE).
Methods: The medical records of 77 HCC patients with 109 HCC nodules who underwent superselective TACE were retrospectively analyzed for LTR. Univariate and multivariate analyses were performed for 16 potential factors using Cox proportional hazard regression. Iodized oil deposition on cone-beam computed tomography (CBCT) imaging was divided into three grades: A=complete tumor staining and complete circumferential safety margin, B=complete tumor staining but incomplete safety margin, C=incomplete tumor staining. The effect of a safety margin on LTR was evaluated by comparison between grade A and B group.
Results: Univariate and multivariate analyses revealed that grade A iodized oil deposition and portal vein visualization were the only two independent significant factors of LTR (P<0.001 and P=0.029, respectively). The 12- and 24-month LTR rates of tumors for grade A (n=62), grade B (n=30), and grade C (n=17) were 16% vs. 41% vs. 100% and 16% vs. 61% vs. 100%, respectively (P<0.001). The tumors in the grade A group had a 75% risk reduction in LTR (odds ratio, 0.25; 95% confidence interval, 0.10 to 0.64; P=0.004) compared to the grade B group.
Conclusions: LTR was significantly lower when a greater degree of iodized oil deposition occurred with a complete circumferential safety margin. In superselective TACE, the safety margin of the embolized areas using intraprocedural CBCT affected LTR in HCC patients

12
권호별 보기
가장 많이 인용된 논문

(자료제공: 네이버학술정보)

가장 많이 인용된 논문
| | | |
1연안해역에서 석유오염물질의 세균학적 분해에 관한 연구

(2006)홍길동 외 1명심리학41회 피인용

다운로드

2미국의 비트코인 규제

(2006)홍길동심리학41회 피인용

다운로드

가장 많이 참고한 논문

(자료제공: 네이버학술정보)

가장 많이 참고한 논문

다운로드

2미국의 비트코인 규제

(2006)홍길동41회 피인용

다운로드

해당 간행물 관심 구독기관

대구보건대학교 연세대학교 대전대학교 경희대학교 부산대학교
 86
 51
 39
 38
 25
  • 1 대구보건대학교 (86건)
  • 2 연세대학교 (51건)
  • 3 대전대학교 (39건)
  • 4 경희대학교 (38건)
  • 5 부산대학교 (25건)
  • 6 대전과학기술대학교 (25건)
  • 7 우송대학교 (22건)
  • 8 동국대학교 (21건)
  • 9 충청대학교 (21건)
  • 10 경복대학교 (18건)

내가 찾은 최근 검색어

최근 열람 자료

맞춤 논문

보관함

내 보관함
공유한 보관함

1:1문의

닫기